Orkambi (lumacaftor) is a small molecule pharmaceutical. Lumacaftor was first approved as Orkambi on 2015-07-02. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Orkambi's patents are valid until 2030-12-11 (FDA).
|Drug Class||Cystic fibrosis transmembrane regulator (CFTR) protein modulators|